The sodium-glucose cotransporter-2 inhibitor dapagliflozin improved A1c and kidney function with just 1 case of mild diabetic ketoacidosis, although blood ketones increased.
ORLANDO, Florida — A low dose of the sodium-glucose cotransporter-2 inhibitor dapagliflozin combined with insulin improved glycemic control and slowed kidney function decline in adolescents with type 1 diabetes , new trial results showed.
Currently, the SGLT2i drug class is not approved by the US Food and Drug Administration for use in people with type 1 diabetes. The ATTEMPT trial showed that"low-dose SGL2i, in this case dapagliflozin 5 mg, can be safely given to adolescents and youth with type 1 diabetes to ameliorate kidney function decline and optimize glycemic control," Mahmud said.
The group receiving dapagliflozin experienced a significant attenuation in the direct evaluation of the"good standard" measured glomerular filtration rate. A1c also declined significantly, by 0.48 percentage points ."We see ketosis in both groups because these individuals have type 1 diabetes," Mahmud commented.
Diabetes Mellitus Type I Type 1 Diabetes Type 1 DM T1DM T1D Renal Disease Kidney Disease Kidney Disorder Renal Disorder Nephropathy Kidneys Chronic Renal Failure Chronic Kidney Failure CKD - Chronic Kidney Disease Chronic Kidney Disease CKD Renal Failure Renal Insufficiency Kidney Insufficiency Kidney Failure Renal Impairment Diabetes Mellitus Type 2
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Early detection of Type 1 diabetes can save children’s livesType 1 diabetes patients and their families want the public to know the signs and symptoms so they can get an early diagnosis. Hydrating in the summer is important, but looking out for excessive thirst and increased urination is necessary.
Read more »
Updated Guideline Reflects New Drugs for Type 2 DiabetesThe American College of Physicians updated its existing guidelines to incorporate evidence on the new treatments for type 2 diabetes.
Read more »
More and More Are Living With Type 1 Diabetes Into Old AgeGlobal prevalence among adults aged 65 and older nearly doubled from 1990 to 2019.
Read more »
Intermittent fasting over two days can help people with Type 2 diabetesA study found that intermittent fasting had striking metabolic benefits that surpassed the effects of prescription drugs for people with newly diagnosed diabetes.
Read more »
Inhaled Insulin Plus Degludec an Option for Type 1 DiabetesUse of premeal Afrezza insulin plus long-acting degludec insulin was non-inferior to automated insulin delivery or multiple daily-injection regimens, but it isn't for everyone.
Read more »
Intermittent fasting over two days can help people with Type 2 diabetesA study found that intermittent fasting had striking metabolic benefits that surpassed the effects of prescription drugs for people with newly diagnosed diabetes.
Read more »